BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 5
• 6
• 7
• 8
• 9
• 12
• 13
• 14
• 15
• 16
• 19
• 20
• 21
• 22
• 23
• 27
• 28
• 29
• 30

• FDA

  FDA Green Lights Novel Merck & Co., Inc. Drug To Prevent Heart Attacks And Strokes

  May 8, 2014

   · 

  2 min read
• Business

  Lundbeck Inc. Swallows Up Chelsea Therapeutics, Inc. In Deal Worth $658 Million

  May 8, 2014

   · 

  14 min read
• Job Trends

  Cash-Strapped Cytomedix Inc. To Shutter North Carolina Facility, Reports Results Of RECOVER-Stroke Phase 2 Study

  May 8, 2014

   · 

  7 min read
• Drug Development

  Novan Therapeutics’ Positive Phase 2 Results Provide Foundation For SB204 As A Non-Antibiotic, First-In-Class Product To Treat Acne Vulgaris

  May 8, 2014

   · 

  2 min read
• Drug Development

  Synta Pharmaceuticals Announces Results From Final Analysis Of The GALAXY-1 Trial Of Ganetespib In NSCLC

  May 8, 2014

   · 

  1 min read
• FDA

  FDA Approves Genentech And Novartis AG’s Xolair For Treatment Of Chronic Hives

  May 8, 2014

   · 

  2 min read
• Policy

  Feds Investigate St. Jude Medical For Potential FCA Violations

  May 8, 2014

   · 

  1 min read
• Drug Development

  AstraZeneca PLC Jumps Start Late-Stage Study Of Key New Cancer Drug

  May 8, 2014

   · 

  4 min read
• Deals

  Merck & Co., Inc. Taking A Break From Dealmaking: CEO

  May 8, 2014

   · 

  1 min read
• Business

  Synta Pharmaceuticals Reports First Quarter 2014 Financial Results and Provides Corporate Update

  May 8, 2014

   · 

  1 min read